Why Did Novartis/1A Pharma Withdraw Its Paracetamol Liquid From The German Market?
HBW Insight chats with general manager of Novartis' German subsidiary 1A Pharma about the firm's exit from the country's children's fever category. An inflexible price system for reimbursable medicines and inflationary pressures all contributed to the decision, Michael Klein explains, which has left only two manufacturers supplying the OTC liquid paracetamol market.
You may also be interested in...
Inflation, new COVID-19 waves and delayed cold and flu outbreaks are causing disruption to Europe's paracetamol supply chain, according to an investigation by HBW Insight. Industry is not currently concerned, but regulators, for example in France, are introducing measures to prevent this issue spreading from children's to adult forms of the drug, as well as to ibuprofen-based alternatives.
Industry actors and outsiders alike discussed existing challenges for the EU healthcare system amid significant economic pressures, while calling for action to ensure a workable system for low-priced medicines.
More medicines available without a prescription and more responsibility for community pharmacists are two of the goals set out by the UK's new Secretary of State for Health and Social Care.